Claim your 30% discount on Global Market Reports with code ONLINE30. Limited time only.

What Is the Forecast for the Uterine Fibroid Embolization Device Market Growth in 2025?

The market size for uterine fibroid embolization devices has robustly expanded in recent years. The market is projected to grow from $5.62 billion in 2024 to $5.93 billion in 2025, exhibiting a compound annual growth rate (CAGR) of 5.6%. This increasing growth in the past years can be credited to a rise in uterine fibroid cases, a preference for non-surgical treatments, initiatives for awareness and education, a concentration on women’s health, a shift towards outpatient services, and doctor training programs.

What Is the Forecast for the Uterine Fibroid Embolization Device Market Size Through 2029?

The market for uterine fibroid embolization devices is projected to steadily increase in the coming years, reaching $7.04 billion in 2029 with a CAGR of 4.4%. This growth during the forecast period can be accredited to heightened awareness about non-invasive treatment options, global expansion of healthcare services, increased focus on women’s health initiatives, integration of multidisciplinary care, and the broadening of outpatient care services. Key market trends for the forecast period encompass the rising adoption of minimally invasive surgeries, the advancement in embolic agents, personalized treatment strategies, emphasis on outpatient UFE procedures, the integration of imaging technologies, and research into bioresorbable embolic agents.

Download The Free Sample Report Here:

https://www.thebusinessresearchcompany.com/sample.aspx?id=13551&type=smp

What are the Key Market Players in Uterine Fibroid Embolization Device Market and How They’re Evolving?

Major companies operating in the uterine fibroid embolization device market report are Johnson and Johnson Pvt Ltd., Abbott Laboratories, Medtronic plc., Siemens Healthineers Ltd., Koninklijke Philips N.V., Stryker Corporation, Boston Scientific Corporation, GE HealthCare Technologies Inc., Olympus Corporation, Terumo Corporation, Smith and Nephew plc., Ethicon Inc., Hologic Inc., CooperSurgical Inc., Ferring B.V., Cook Medical Inc., Karl Storz GmbH, Merit Medical Systems, CONMED Corporation, Amsino International Inc., Lumenis Ltd., Richard Wolf GmbH, BTG International Ltd., Healthium MedTech Pvt. Ltd., INSIGHTEC Ltd., Hironic Co.Ltd., Minerva Surgical Inc., Gynesonics Inc., Advanced Surgical Concepts PLLC, Hitachi Medical Corporation

What Are the Primary Growth Drivers in the Uterine Fibroid Embolization Device Market?

The surge in demand for less invasive surgical procedures is forecasted to significantly boost the uterine fibroid embolization device market’s growth. These surgeries denote methods that use small entry points or natural body orifices to treat various internal organs and structures, minimizing physical trauma inflicted on the patient. Uterine fibroid embolization devices, integral to these procedures, are specifically designed to reduce invasiveness, causing less damage to adjacent tissues. They also address the rising demand for less invasive healthcare procedures, resulting in better patient outcomes. For example, The Aesthetic Society, a US-based organization focused on plastic surgery and cosmetic medicine, reported in August 2023 that Americans spent over $11.8 billion on aesthetic procedures, a 2% increase from the prior year. Hence, the escalating demand for less invasive surgeries fuels the growth of the uterine fibroid embolization device market.

Uterine Fibroid Embolization Device Market Driver: Growing Elderly Population Spurs Uterine Fibroid Embolization Devices Market Expansion

Request For A Customized Report:

https://www.thebusinessresearchcompany.com/customise?id=13551&type=smp

What Are the Leading Segments in the Global Uterine Fibroid Embolization Device Industry?

The uterine fibroid embolization device market covered in this report is segmented –

1) By Technology: Surgical Techniques, Laparoscopic Techniques, Ablation Techniques, Embolization Techniques

2) By Mode Of Treatment: Invasive Treatment, Minimally Invasive Treatment, Non-Invasive Treatment

3) By End User: Hospitals, Clinics, Ambulatory Surgical Center

Subsegments:

1) By Surgical Techniques: Open Surgery, Myomectomy

2) By Laparoscopic Techniques: Laparoscopic Myomectomy, Laparoscopic Hysterectomy

3) By Ablation Techniques: Radiofrequency Ablation, Microwave Ablation, Cryoablation

4) By Embolization Techniques: Transcatheter Arterial Embolization (TAE), Uterine Artery Embolization (UAE)

What Are the Key Market Trends in the Uterine Fibroid Embolization Device Industry?

Major industry players in the uterine fibroid embolization device market are escalating their game by creating cutting-edge products, such as the TruClear system. This innovative solution was initiated to meet the escalating demand for minimally invasive therapies for uterine fibroids and enhance the safety and effectiveness of uterine fibroid treatments. The TruClear system is a flexible catheter used as a mechanical hysteroscopic tissue removal instrument for addressing intrauterine abnormalities (IUA), and it is inserted into the uterus via the cervix. For instance, in November 2022, Medtronic Private Limited, an industry-leading medical equipment manufacturer based in India, introduced the innovative TruClear system. As a mechanical hysteroscopic tissue removal system, it provides a secure and potent solution for treating IUA. Furthermore, its compact size, flexibility, nitinol wire loop, continuous inflow and outflow, built-in suction, and high-definition imaging features contribute to the enhancement of precision and safety when conducting uterine fibroid treatments.

Access The Full Report Here:

https://www.thebusinessresearchcompany.com/report/uterine-fibroid-embolization-device-global-market-report

What Is the Regional Outlook for the Uterine Fibroid Embolization Device Market?

North America was the largest region in the uterine fibroid embolization device market in 2024. The regions covered in the uterine fibroid embolization device market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Purchase The Full Report Today:

https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=13551

This Report Delivers Insight On:

1. How big is the uterine fibroid embolization device market, and how is it changing globally?

2. Who are the major companies in the uterine fibroid embolization device market, and how are they performing?

3. What are the key opportunities and risks in the uterine fibroid embolization device market right now?

4. Which products or customer segments are growing the most in the uterine fibroid embolization device market?

5. What factors are helping or slowing down the growth of the uterine fibroid embolization device market?

About The Business Research Company:

With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795

Asia +44 2071930708

Europe +44 7882 955267

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model